Ubs Group Ag Rani Therapeutics Holdings, Inc. Transaction History

Ubs Group Ag

$555 Billion
Q2 2025

A detailed history of Ubs Group Ag transactions in Rani Therapeutics Holdings, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 62,064 shares of RANI stock, worth $32,893. This represents 0.0% of its overall portfolio holdings.

Number of Shares

62,064

Previous 72,117 13.94%

Holding current value

$32,893

Previous $90,000 65.56%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	SELL	$0.48 - $1.39 $4,825 - $13,973	-10,053 Reduced 13.94%	62,064 $31,000
Q1 2025 May 13, 2025	BUY	$1.25 - $1.85 $60,740 - $89,895	48,592 Added 206.55%	72,117 $90,000
Q4 2024 Feb 14, 2025	BUY	$1.3 - $3.18 $10,160 - $24,854	7,816 Added 49.75%	23,525 $32,000
Q3 2024 Nov 14, 2024	BUY	$2.06 - $3.99 $26,180 - $50,708	12,709 Added 423.63%	15,709 $33,000
Q1 2024 May 13, 2024	BUY	$2.98 - $3.8 $8,940 - $11,400	3,000 New	3,000 $9,000
Q3 2023 Nov 09, 2023	BUY	$2.17 - $4.44 $3,662 - $7,494	1,688 Added 42.07%	5,700 $12,000
Q2 2023 Aug 11, 2023	BUY	$3.92 - $5.58 $11,807 - $16,806	3,012 Added 301.2%	4,012 $16,000
Q3 2022 Nov 10, 2022	SELL	$8.23 - $12.4 $12,657 - $19,071	-1,538 Reduced 60.6%	1,000 $10,000
Q2 2022 Aug 10, 2022	SELL	$8.0 - $14.25 $8,256 - $14,706	-1,032 Reduced 28.91%	2,538 $26,000
Q1 2022 May 16, 2022	SELL	$12.21 - $23.14 $19,792 - $37,509	-1,621 Reduced 31.23%	3,570 $48,000
Q4 2021 Feb 14, 2022	BUY	$16.09 - $35.0 $34,126 - $74,235	2,121 Added 69.09%	5,191 $85,000
Q3 2021 Nov 15, 2021	BUY	$10.7 - $21.43 $32,849 - $65,790	3,070 New	3,070 $55,000

Others Institutions Holding RANI

# of Institutions

Shares Held

6.32M

Call Options Held

29.4K

Put Options Held

View Full List

About Rani Therapeutics Holdings, Inc.

Ticker RANI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 24,492,000
Market Cap $13M
Description
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing. Its product pipeline includes RT-101, an octreotide, which has completed P...

More about RANI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account